XML 40 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document and Entity Information - USD ($)
$ in Billions
 12 Months Ended
Dec. 31, 2022
Feb. 21, 2023
Jun. 30, 2022
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2022    
Document Fiscal Year Focus 2022    
Document Fiscal Period Focus FY    
Trading Symbol VIR    
Title of 12(b) Security Common Stock, $0.0001 par value    
Security Exchange Name NASDAQ    
Entity Registrant Name Vir Biotechnology, Inc.    
Entity Central Index Key 0001706431    
Current Fiscal Year End Date --12-31    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
Entity Common Stock, Shares Outstanding   133,531,379  
Entity Public Float     $ 2.0
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Shell Company false    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Document Annual Report true    
Document Transition Report false    
Entity File Number 1-39083    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 81-2730369    
Entity Address, Address Line One 499 Illinois Street    
Entity Address, Address Line Two Suite 500    
Entity Address, City or Town San Francisco    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 94158    
City Area Code 415    
Local Phone Number 906-4324    
ICFR Auditor Attestation Flag true    
Documents Incorporated by Reference

Portions of the definitive proxy statement, or the Proxy Statement, for the Registrant’s 2023 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K. The Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of the Registrant’s fiscal year ended December 31, 2022.

    
Auditor Firm ID 42    
Auditor Name Ernst & Young LLP    
Auditor Location San Mateo, California